newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
President Donald Trump announced a deal with drugmaker Regeneron to lower drug costs for Medicaid recipients.
President Trump announced a pricing agreement with Regeneron to lower Medicaid drug costs.
KEY POINTS
Regeneron's cholesterol drug Praluent will be sold for $225 on the TrumpRx platform.
The deal is part of 'most-favored-nation' agreements to align U.S. drug prices internationally.
Regeneron committed to increased U.S. research and development investment as part of the agreement.
Regeneron's new gene therapy received FDA approval amid ongoing drug pricing debates.
In a significant move on Thursday, President Donald Trump revealed a groundbreaking agreement with drugmaker Regeneron aimed at lowering pharmaceutical costs for Medicaid recipients. This aligns with the White House's broader initiative to address high drug prices ahead of the midterm elections, reflecting Trump's ongoing efforts to achieve economic relief, particularly in healthcare.
Under the deal, Regeneron will reduce prices for its existing and future drugs, including the cholesterol medication Praluent, which will be available for USD 225 on the discounted platform TrumpRx. This agreement, part of several 'most-favored-nation' deals, aims to bring U.S. drug prices in line with those of other developed countries.
The President, with a history of lauding Regeneron, emphasized the potential electoral impact of such deals and mentioned Regeneron's commitment to substantial research and development investments in the U.S. Additionally, Regeneron's new gene therapy was approved by the FDA, underscoring the ongoing debate over drug-pricing strategies during Trump's administration.